ACA
DAWN

Apis Capital Advisors’s Day One Biopharmaceuticals DAWN Stock Holding History

Apis Capital Advisors’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-29,000
Closed -$356K – 29
2023
Q3 		$356K Sell
29,000
-61,000
-68% -$796K 0.46% 19
2023
Q2 		$1.07M Buy
+90,000
New +$1.18M 1.08% 18

Other funds holding DAWN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Apis Capital Advisors's DAWN Position: Q4 2023 in Review

Apis Capital Advisors sold out of Day One Biopharmaceuticals (DAWN) in Q4 2023, closing a stake of 29,000 shares — an estimated $356K sold.

Apis Capital Advisors first reported a position in DAWN in Q2 2023 and held it in 2 quarters. The position peaked at $1.07M in Q2 2023. 139 funds tracked by Wall St. Rank hold DAWN as of Q4 2023.

  • Apis Capital Advisors reported no remaining Day One Biopharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Apis Capital Advisors sold 29,000 Day One Biopharmaceuticals shares in Q4 2023, an estimated $356K.
  • Apis Capital Advisors first reported a position in Day One Biopharmaceuticals in Q2 2023 and held it in 2 quarters.
  • Apis Capital Advisors's Day One Biopharmaceuticals position peaked at $1.07M in Q2 2023.
  • 139 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q4 2023.

Based on Apis Capital Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.